The RAINBOW and TAGS trials have demonstrated strong evidence to support the use of ramucirumab and TAS-102 in patients with advanced gastric or gastroesophageal cancer who have progressed on first-line therapy.
Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.
Thanks to technological advances, the past several decades have witnessed a blossoming appreciation of the varied composition of these microbial communities, their complex and dynamic relationship with the host, and the way they affect health and disease.
Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.
SM-88, a novel compound that attacks oncogenic metabolic pathways, is under development for patients with metastatic pancreatic cancer and other solid tumors, raising the potential for a tumor-agnostic therapy.
Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.
Rachna T. Shroff, MD, MS, highlighted the ongoing research efforts in biliary tract cancers, specifically with cholangiocarcinoma treatment.
Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.
John Strickler, MD, discusses how liquid biopsies are being used to help guide treatment decisions for patients with GI cancers and shed light on other research efforts that are being made to improve outcomes.
Vincent Chung, MD, discusses the therapeutic landscape of early-stage and advanced pancreatic cancer.